Objective: To evaluate the ability of epithelial-to-mesenchymal transitionrelated microRNAs (miRNAs) as serum biomarkers for prognosis and prediction of metastasis in patients with colorectal cancer (CRC). Background: Epithelial-to-mesenchymal transition-related miRNAs drive CRC progression and metastasis. However, their potential as serum biomarkers in CRC has not been studied. Methods: This was a 3-phase study using 446 colorectal specimens. In the first phase, we selected candidate miRNAs associated with metastasis by analyzing the expression of 4 miR-200 family members (miR-200b, -200c, -141, and -429) in serum samples from 12 patients with stage I and IV CRC. The second phase involved independent validation of candidate miRNAs in serum from 182 patients with CRC and 24 controls. Finally, we analyzed expression in matched 156 tumor tissues from 182 patients with CRC and an independent set of 20 matched primary CRC and corresponding liver metastases to identify the source of circulating miRNAs. Results: After initial screening, miR-200c was selected as the candidate serum miRNA best associated with metastasis. Validation analysis revealed that serum miR-200c levels were significantly higher in stage IV than in stage I-III CRCs. High serum miR-200c demonstrated a significant positive correlation with lymph node metastasis, distant metastasis, and prognosis (P = 0.0026, P = 0.0023, and P = 0.0064, respectively). More importantly, serum miR-200c was an independent predictor for lymph node metastasis (odds ratio: 4.81, 95% confidence interval: 1.98-11.7, P = 0.0005) and tumor recurrence (hazard ratio: 4.51, 95% confidence interval: 1.56-13.01, P = 0.005) and emerged as an independent prognostic marker for CRC (hazard ratio: 2.67, 95% confidence interval: 1.28-5.67, P = 0.01). Conclusions: Serum miR-200c has strong potential to serve as a noninvasive biomarker for CRC prognosis and predicting metastasis.
C olorectal cancer (CRC) is one of the most common malignancies worldwide and is a major cause of cancer-related deaths. 1 Survival rates of patients with CRC have increased in the past few years, possibly as a result of earlier diagnosis and improved treatment regimens; nonetheless, approximately 30% to 50% of patients who undergo curative resection subsequently experience local tumor recurrence or metastasis. 2 This subgroup of patients usually receives chemotherapy, often in combination with monoclonal antibody therapy, with a median overall survival duration of approximately 20 months and the response rates at best around 50%. 3 However, the substantial financial costs associated with CRC treatment not only present an economic burden, but treatment of all patients with chemotherapy without a priori selection leads to overtreatment with toxic agents that produce severe adverse effects. 4 To overcome this clinical challenge, there is a clear need to identify biomarkers that will facilitate the identification of patients with a poor prognosis and permit personalized treatment strategies for patients with a high risk of CRC recurrence.
Blood-based tumor markers are gaining acceptance as a potential alternative for noninvasive detection of cancer. Serum carcinoembryonic antigen (CEA) is one marker that is frequently used for predicting prognosis in patients with CRC. 5, 6 Unfortunately, CEA levels do not always correlate with the presence of metastasis, and the incidence of false-positive and false-negative results is very high. 7, 8 Consequently, there is a dire need to identify highly robust biomarkers that can clinically determine cancer prognosis and are better indicators of patient outcome than the existing tumor node metastasis (TNM) staging system or other conventional tumor markers of CRC. 9 MicroRNAs (miRNAs) are noncoding RNA molecules of approximately 21 to 23 nucleotides in length that regulate target gene expression by interfering with their transcription or by inhibiting translation. 10 miRNAs play crucial roles in diverse cellular biological processes, including differentiation, proliferation, growth, migration, and survival. The discovery that miRNA expression is frequently dysregulated in malignant tumors underpins their critical role, which is a matter of active investigation, both from a basic science perspective and for its clinical usefulness. 11 Recently, several studies have highlighted the diagnostic and prognostic utility of plasma and serumbased miRNA levels, because tumor-derived miRNAs are present in human circulation in remarkably stable forms that are protected from endogenous ribonuclease activity. 12 These reports suggest that plasma/serum miRNA-based assays may constitute accurate methods for diagnosis and prognosis of human cancer, although to date only a few studies have specifically addressed the clinical significance of circulating miRNAs in patients with CRC. [13] [14] [15] [16] [17] Epithelial-to-mesenchymal transition (EMT) manifests through downregulation of E-cadherin and successive loss of cell-cell adhesion, leading to a mesenchymal phenotype. 18 This contributes to accelerated invasiveness, dissemination, and metastasis of epithelial tumor cells in several carcinomas, including CRC. [19] [20] [21] The miR-200 family (miR-200a, miR-200b, miR-200c, miR-141, and miR-429) inhibits the E-cadherin-suppressor targets such as zinc reported that dysregulated expression of miR-200b, -200c, -141, and -429 is responsible for the EMT to-mesenchymal-to-epithelial transition (MET) switch in colorectal metastasis. In this study, we for the first time demonstrated that the miR-200c/429 cluster was significantly overexpressed in liver metastasis compared with primary CRC, and the expression of these miRNAs was specifically regulated by aberrant methylation of their promoter regions. 24 Despite their involvement in metastasis, none of the previous studies has explored the clinical significance of miR-200 family expression in serum of patients with CRC.
In view of these limitations in the current literature, we focused this study on the EMT to expression analysis of the miR-200 family (miR-200b, miR-200c, miR-141, and miR-429) in the serum of patients with CRC by adopting a 3-step approach. First, in screening a subset of samples, we selected candidate miRNAs that were associated with metastasis by comparing expression levels in the serum from patients with stage I and stage IV CRC. In the second phase, using a larger and independent cohort of serum specimens from patients with CRC and healthy controls, we validated the clinical significance of selected miRNAs as potential noninvasive biomarkers for predicting metastasis, tumor recurrence, or the prognosis of patients with CRC. Finally, we investigated the expression of selected miRNAs in primary CRC and distant metastasis tissues in an effort to identify the origin of these miRNAs in serum. Using this systematic approach, we demonstrate that serum levels of miR-200c, which is a bona fide EMT-related miRNA, are not only significantly associated with a metastatic phenotype in the colorectum but also serve as a potential biomarker for predicting lymph node metastasis, tumor recurrence, and prognosis in patients with CRC.
METHODS

Study Design and Clinical Specimens
This study included analysis of 446 colorectal specimens which were obtained at Mie University Medical Hospital, Mie prefecture in Japan between 2005 and 2011. This was a 3-phase study, which aimed to screen, validate, and determine the potential involvement of serum miRNAs in patients with CRC.
During the initial screening phase, we analyzed serum levels of several candidate miR-200 families in a subset of 24 serum samples from patients with stage I (n = 12) and stage IV (n = 12) CRC. In the second phase, candidate miRNAs that were overexpressed in serum of stage IV versus stage I patients in the initial screening step were further validated in a larger, independent cohort, which included serum samples from 182 patients with CRC and 24 normal controls. The final phase aimed to evaluate the potential source of miRNAs in the serum in patients with CRC by comparing expression of selected miRNAs in matched surgical Formalin-Fixed Paraffin-Embedded (FFPE) tissues (n = 156) from 182 patients with CRC and 20 adjacent normal mucosa. In addition, we analyzed an independent set of matched primary CRC specimens (n = 20) and their corresponding liver metastasis tissues (n = 20) during this step of the study.
Patients treated with radiotherapy or chemotherapy before surgery were not included in this study. Patients with stage III and IV disease received 5-fluorouracil-based chemotherapy, whereas no adjuvant therapy was given to patients with stage I and II CRC. CEA levels in serum samples were measured by standard enzyme immunoassay as a routine clinical test. Both serum-and tissuebased studies were approved by the institutional review broad of the Mie University Hospital, Japan, and Baylor University Medical Center, Dallas, TX. All participants gave written consent for their information to be stored in the hospital database and used for research.
RNA Isolation From Serum and qRT-PCR
Small RNAs were enriched from all serum samples using the Qiagen miRNAeasy Kit (Qiagen, Valencia, CA). Briefly, 250 μL of serum was thawed on ice and centrifuged at 10,000 rpm for 5 minutes to remove cellular debris. Next, 200 μL of supernatant was lysed with 5 volumes of Qiazol solution. For normalization of sample-tosample variation during the RNA isolation procedures, 25 fmol of synthetic Caenorhabditis elegans miRNA (cel-miR-39) was added to each denatured sample. Small RNAs were then enriched and purified according to the manufacturer's protocol, with the exception that the enriched small RNAs were eluted in 40 μL of preheated nucleasefree water. For miRNA-based RT-PCR assays, 1.67 μL of enriched small RNAs from serum samples was reverse-transcribed using the TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems, San Diego, CA) in a total reaction volume of 5.0 μL, according to the manufacturer's instructions. RT products were diluted 1:15 and used as PCR template. PCR reactions for quantification of miR-200b, miR-200c, miR-141, miR-429, and cel-miR-39 were performed in duplicate using TaqMan 2X Universal PCR Master Mix using conditions described previously. 25 The qRT-PCR reactions were performed using an Applied Biosystems 7000 Sequence Detection System with the following cycling conditions: 95 • C for 10 minutes, followed by 45 cycles of 95 • C for 15 seconds and 60 • C for 1 minute. The cycle threshold (Ct) values were calculated with SDS 1.4 software (Applied Biosystems, Foster City, CA).
RNA Isolation From FFPE Tissues and qRT-PCR
Total RNA was isolated from FFPE samples using the Recover All Total Nucleic Acid Isolation Kit (Ambion Inc, Austin, TX). Briefly, tissue sections were microdissected to enrich for neoplastic cells, followed by deparaffinization and RNA extraction using the manufacturer's protocol. Total RNA was eluted in appropriate buffer and quantified using a NanoDrop spectrophotometer (NanoDrop Technologies, Wilmington, DE). Reverse transcription reactions were carried out using the TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems, San Diego, CA) in a total reaction volume of 15 μL. MiR-200c and miR-16 were quantified in duplicate by qRT-PCR, using TaqMan MicroRNA Assay Kits (Applied Biosystems, Foster City, CA). qRT-PCR was performed on an Applied Biosystems 7000 Sequence Detection System using the following cycling conditions: 95 • C for 10 minutes, followed by 45 cycles of 95 • C for 15 seconds and 60 • C for 1 minute. Ct values were calculated with SDS 1.4 software (Applied Biosystems, Foster City, CA).
Calculation of miRNA Expression
The average expression levels of serum and tissue miRNAs were normalized against cel-miR-39 12,25 and miR-16 26, 27 using the 2 − Ct method. Differences between the groups are presented as Ct, indicating the difference between the Ct value of the miRNA of interest and the Ct value of the normalizer miRNA. To ensure consistent measurements throughout all assays, for each PCR amplification reaction, 3 independent RNA samples were loaded as internal controls to account for any plate-to-plate variation, and the results from each plate were normalized against internal normalization controls.
In Situ Hybridization
Five micrometer-thick FFPE tissue sections were hybridized with the miR-200c probe (LNA-modified and 5 -and 3 -DIG-labeled oligonucleotide; Exiqon, Woburn, MA), followed by incubation with anti-DIG-AP Fab fragments conjugated to alkaline phosphatase, and the hybridization signal was detected by applying nitroblue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate color substrate (Roche Applied Science, Mannheim, Germany). Positive controls (U6 snRNA, LNA-modified and 5 -and 3 -DIG-labeled oligonucleotide; Exiqon) and negative controls (scrambled microRNA control, LNA-modified and 5 -and 3 -DIG-labeled oligonucleotide; Exiqon) were included in each hybridization procedure.
Statistical Analysis
The significance of serum and tissue miRNA levels was determined by the Mann-Whitney U test, the Kruskal-Wallis test, or the χ 2 test where appropriate. Logistic regression analysis was used to predict the factors influencing lymph node metastasis. Overall and disease-free survival curves were analyzed using Kaplan-Meier method, and differences were examined using log-rank tests. Cox proportional hazard regression test was used to estimate univariate and multivariate hazard ratios for recurrence and prognosis. Receiver operating characteristic curves with Youden Index correction 28 were established for determining optimal miRNA expression cutoff thresholds for analyzing lymph node metastasis prediction, disease-free survival, and overall survival. All P values were 2-sided, and those less than 0.05 were considered statistically significant. All statistical analyses were carried out using Medcalc 7.2 for Windows (Broekstraat 52, 9030, Mariakerke, Belgium).
RESULTS
Serum miR-200c Is a Candidate miRNA That Is Associated With CRC Metastasis
In the initial screening step aimed at identifying metastasisassociated serum miRNA biomarkers as noninvasive prognostic markers, we investigated the relative expression levels of the miR-200 family (miR-200b, miR-200c, miR-141, and miR-429) in a subset of serum specimens from 12 patients with stage IV and 12 patients with stage I CRC (Supplemental Digital Content Table S1 , available at http://links.lww.com/SLA/A444). Among all miRNA analyzed ( Fig. 1 ), miR-200c was significantly elevated in the serum of patients with stage IV compared with stage I CRC (P < 0.05; Fig. 1B ). In contrast, no significant differences were observed in miR-141, miR-200b, and miR-429 expression between patients with stage I and stage IV CRC ( Fig. 1A , C, and D). On the basis of these observations, we subsequently focused on validating and further exploring the clinical significance of miR-200c in an independent set of serum samples from 182 patients with CRC. In addition, we also attempted to investigate the potential origin of miR-200c in serum by analyzing matched serum and tumor tissue samples from patients who had matched primary tissues from 182 patients with CRC and an independent set of tissues from 20 pairs of primary CRCs and matched liver metastases.
Serum miR-200c Expression Levels Serve as a Predictive and Prognostic Biomarker in Patients With CRC
Patient characteristics and distribution of tumor stages are summarized in Supplemental Digital Content Table S2 , available at http://links.lww.com/SLA/A445. There were no significant differences in the mean age between patients with CRC (67 ± 10.4 years) and healthy controls (64 ± 12.9 years; P > 0.05; analysis of variance). The gender distribution in the CRC group was 105:77 (males:females), and in the control group it was 13:11 (P > 0.05; χ 2 test). For miR-200c expression analysis in matched primary CRC tissues and serum, 156 of 182 samples were available from the CRC patient cohort.
Serum miR-200c Levels Predict Lymph Node Metastasis in Patients With CRC
The expression levels of serum miR-200c in CRC were significantly higher than that in normal controls (P = 0.015; Fig. 2A ). Serum miR-200c levels were significantly higher in patients with stage IV CRC than in normal controls, and in patients with stage I, II, and III CRC (Fig. 2B ). The potential clinical significance of serum miR-200c expression is presented in Table 1 . As shown, high expression of serum miR-200c was associated with a metastatic phenotype, including lymph node metastasis (P = 0.0026), liver metastasis (P = 0.0015), and the development of distant metastases (P = 0.0023) in patients with CRC. We next analyzed miR-200c levels in serum on the basis of pathological extension of colorectal neoplasia to hepatic or lymph node metastasis. We first determined associations between miR-200c expression and the H-classification of CRCs, with H0 indicating no liver metastasis, H1 representing liver metastasis with less than 5 nodules smaller than 5 cm, H2 indicative of metastasis that does not involve H1 and H3, and H3 indicating liver metastasis with more than 5 metastasis larger than 5 cm. The miR-200c levels were significantly higher in patients with H3 CRC than those in patients with H0 or H1-2 CRC (P < 0.0001; Fig. 2C ). Likewise, serum expression of miR-200c was significantly higher in patients with lymph node metastasis to the aorta (N3) than in those with regional (N1-2: P = 0.003; Fig. 2D ) or absent lymph node metastasis (N0: P = 0.01; Fig. 2D ) in patients with CRC. In addition, in stage I-III patients, serum miR-200c expression increased in accordance with progression of lymph node metastasis, and miR-200c expression in N3 patients was significantly higher than that in N0 patients (P = 0.036; Supplemental Digital Content Fig.  S1A , available at http://links.lww.com/SLA/A442). Furthermore, in stage II-III CRCs, serum miR-200c expression of lymph nodepositive patients (stage III) was significantly higher than that of lymph node-negative patients (stage II) (P = 0.037; Supplemental Digital Content Fig. S1B , available at http://links.lww.com/SLA/A442). Taken together, these results indicate that serum miR-200c levels in CRC could be influenced by tumor volume or its dissemination to lymph node or hepatic metastatic sites.
To further evaluate whether serum miR-200c levels can serve as a predictor of lymph node metastasis, we performed logistic regression analysis. Univariate analysis demonstrated that highly invasive tumors (T3/4; P = 0.0024), with lymphatic (P < 0.0001) and venous invasion (P = 0.0001), high CEA levels (P = 0.0001), and high levels of serum miR-200c (P = 0.0001) were all significantly associated with lymph node metastasis (Table 2 ). Furthermore, serum miR-200c expression was an independent predictor of lymph node metastasis in CRC based upon multivariate logistic regression analysis [hazard ratio (HR) = 4.81, 95% confidence interval (CI) = 1.98-11.7; P = 0.0005], suggesting that serum miR-200c as a predictor of lymph node metastasis is superior to pathological findings that are known to be risk factors.
Serum miR-200c Is a Prognostic and Tumor Recurrence Predictive Biomarker in CRC
To further evaluate whether serum miR-200c levels can predict CRC prognosis, we next performed survival analysis. Kaplan-Meier analysis showed that patients with higher levels of serum miR-200c had significantly poorer survival than those with lower expression of this miRNA in patients with stage I-IV and II-IV CRC, respectively (P = 0.0064 and P = 0.0030; log-rank test; Fig. 3A, B) . In contrast, miR-200c levels in CRC tissues were not significantly associated with survival in patients with stage I-IV and II-IV CRC, respectively (P = 0.0935 and P = 0.154; log-rank test; Fig. 3C, D) . To determine whether serum miR-200c expression was an independent risk factor for prognosis, the Cox proportional hazard regression model was employed (Table 3 ). In univariate analysis, high levels of miR-200c in serum (P = 0.006), high levels of CEA (P = 0.0001), high pathological T stage (T3/4; P = 0.0024), lymph node metastasis (P < 0.0001), poor differentiation (P = 0.036), and high TNM stage (stage III/IV; P < 0.0001) were significantly associated with poor prognosis. On the contrary, multivariate analysis showed that high serum miR-200c expression was an independent prognostic marker for predicting poorer overall survival in patients with CRC (HR = 2.67, 95% CI = 1.28-5.67; P = 0.01; Table 3 ). In addition, patients with high serum miR-200c in stage II but not in stage III had shorter disease-free survival than those with low serum miR-200c, respectively (P = 0.025, log-rank test; Supplemental Digital Content Fig. S2A , available at http://links.lww.com/SLA/A443; P = 0.11, log-rank test; Supplemental Digital Content Fig. S2B , available at http://links.lww.com/SLA/A443). To determine whether serum miR-200c can serve as a predictor of tumor recurrence after curative surgery (stage II-III), the Cox proportional hazard regression model was utilized (Table 4 ). Univariate analysis showed that venous invasion (positive; P = 0.038), lymph node metastasis (P = 0.0015), and high serum miR-200c levels (P = 0.024) were significantly associated with disease-free survival. In contrast, multivariate analysis revealed that high serum miR-200c was an independent predictor for tumor recurrence in patients with stage II-III CRC (HR = 4.51, 95% CI = 1.56-13.01; P = 0.005). In addition, high serum miR-200c expression was the only factor that allowed prediction of patients with stage II CRC who experienced tumor recurrence (HR = 8.43, 95% CI = 1.00-72.96; P = 0.01; Table 5 ). Therefore, serum miR-200c levels may not only serve as a predictive marker of lymph node metastasis but also predict poor prognosis and early recurrence in patients with higher accuracy than serum CEA levels or pathological staging.
Investigation of the miR-200c Source in Serum of Patients With CRC
In an effort to determine whether miR-200c levels in serum are of tumor origin, we quantified the expression levels of miR-200c in matched CRC tissues. As expected, miR-200c expression in CRC tissues was significantly higher than in normal colonic mucosa (P = 0.0043; Fig. 4A) . Surprisingly, however, miR-200c levels in CRC tissues gradually decreased with increasing tumor stage, and the levels in stage IV CRCs were significantly lower than in stage I CRC (P = 0.0253; Fig. 4B ), suggesting a lack of direct correlation between serum and matched tissue miR-200c expression. In addition, there were no associations between miR-200c expression in CRC and clinicopathological findings, except for lymphatic invasion ( Table 1 , Fig. 3C, D) . We next analyzed miR-200c expression in both primary CRC and matched liver metastases from 20 independent CRC patients. Of interest, the levels of miR-200c in liver metastases were significantly higher than in primary CRC (P = 0.0135; Fig. 4C ). Furthermore, we also confirmed miR-200c expression in both primary CRC tumors and matched liver metastases by in situ hybridization, illustrating that miR-200c was highly expressed in liver metastases compared with primary CRC (Fig. 4D) . Taken together, we hypothesize that a potential source of miR-200c in serum of patients with CRC might be the metastatic sites; hence, serum miR-200c levels may serve as a superior metastasis, recurrence-predictive and prognostic marker of CRC.
DISCUSSION
This study investigates the potential clinical utility of 4 critical miR-200 family members to serve as noninvasive prognostic and metastasis-predictive biomarkers in patients with CRC. To this end, in a small screening subset, we found that serum miR-200c levels in stage IV CRCs were significantly higher than in stage I CRC. Accordingly, we selected miR-200c and subsequently validated it as a candidate serum miRNA with potential promise as a predictive biomarker for metastasis in CRC. We performed independent validation experiments using a large cohort of samples from 182 patients with CRC and 24 control subjects. These data provided strong evidence that serum miR-200c levels in patients with CRC were significantly higher than in healthy controls. Furthermore, serum miR-200c levels were significantly higher in patients with stage IV CRC than in stage I-III CRC. In addition, high serum miR-200c levels were associated with shorter overall survival and served as an independent prognostic biomarker in patients with CRC. Interestingly, instead of lymph node metastasis, serum miR-200c was the best independent predictor of tumor recurrence in patients with stage II-III CRC. From a clinical standpoint, our study showed that the preoperative serum miR-200c expression was the only factor for detecting early tumor recurrence in patients with stage II CRC, a target population that can significantly benefit from timely clinical intervention and result in an improvement of cancer survival in patients with this malignancy. Collectively, these results indicate that evaluation of miR-200c in patients with CRC presents a clinically promising biomarker that can facilitate disease risk assessment and severity in patients with CRC. Our data are of particular interest because these highlight that overexpression of miR-200c in serum provided an independent predictor of lymph node metastasis. Currently, there are several options for curative treatment of early CRC without lymph node metastasis, including endoscopic mucosal resection, endoscopic submucosal dissection, and laparoscopic-assisted partial colectomy. However, the routine choice of these less invasive treatments is essentially determined by the clinicopathological findings that include macroscopic type, tumor size, presence of an ulcer, and the histology of biopsy specimens. 29, 30 Considering the clinical challenge that a significant proportion of these patients are erroneously misdiagnosed using these conventional pathological criteria, incorporation of more robust molecular biomarkers such as quantification of miR-200c expression in serum, followed by preoperative selection of patients without lymph node metastasis may be possible and could promote minimally invasive treatments of early CRC. The miR-200 family is known to inhibit EMT by maintaining the epithelial phenotype through directly targeting the E-cadherin transcriptional repressors ZEB1 and ZEB2, thereby inducing upregulation of E-cadherin. 31 Conversely, inhibition of the miR-200 family induces mesenchymal-like spindle morphology, accompanied by an increase in cell invasion and migration, which is considered to be an important initial step in the metastatic spread of cancer. 31 Once metastasized, cancer cells undergo MET, a process that facilitates the subsequent settlement and proliferation of metastasized cells in distant organs. 32 Furthermore, we recently demonstrated that miR-200c is overexpressed in metastatic CRC compared with matched primary CRC and its expression is epigenetically regulated. 24 These data collectively indicate that the miR-200 family, in particular, miR-200c, plays a critical role in regulating the EMT-MET switch to assist cancer cells moving from local to distant sites and establishing metastatic tumors.
Considering the role of the EMT-MET processes in mediating and facilitating tumor metastasis, the source of miR-200c in serum is intriguing. In this study, we observed a gradual decrease in tissue miR-200c expression in matched primary CRC tissues in a stage-dependent manner, with significantly lower expression in stage IV CRCs. Consequently, the significant elevation of miR-200c expression in the serum of patients with stage IV CRC was not reflected in primary CRC tissues. In contrast, miR-200c was significantly overexpressed in liver metastases compared with matched primary CRCs, which was consistent with markedly high intensity in situ expression of miR-200c in the liver metastasis. Furthermore, high levels of miR-200c in serum were significantly associated with metastasis to lymph nodes, liver, and to other organs. Interestingly, the increase in serum miR-200c levels occurred in accordance with the N category in the TNM classification and the H-system of the Japanese Society for Cancer of the Colon and Rectum, 33 in which metastases are classified according to the size of maximum metastasis diameter and the number of metastases. Although speculative, our results suggest that the origin of serum miR-200c from patients with metastasis might be from the metastatic site, possibly reflecting release of cancer cells into the systemic circulation in CRC patients. Alternatively, the fall in tissue miR-200c might reflect changes taking place in the primary tumor associated with EMT that facilitate exit from the primary tumor, a process that is later reversed in the metastatic deposit.
CONCLUSIONS
This study demonstrates several novel pieces of evidence favoring serum levels of miR-200c as a robust prognostic and metastasispredictive biomarker in patients with CRC. First, miR-200c in serum was significantly associated with a metastatic phenotype in CRC; particularly, serum miR-200c expression is a good predictive marker of lymph node metastasis in CRC. Second, miR-200c in serum is an independent prognostic marker and predictive biomarker of tumor recurrence in patients undergoing curative surgery, especially stage II CRCs, and seems to be superior to CEA levels or pathological TNM staging in patients with CRC. Finally, our data suggest that the source of miR-200c in serum might be contributed by foci of tumor metastasis within lymph nodes, liver, or other distant organs. Therefore, we propose that evaluation of preoperative serum miR-200c is a promising clinical tool for determining tumor recurrence and overall prognosis and, in particular, might aid in the identification of patients with micrometastasis who require intensive monitoring after surgery.
